Stemtech Corp 8-K, filed Apr 14, 2025
Stemtech Corp (STEK)
About this 8-K
Stemtech Corp filed this 8-K on April 14, 2025, reporting on events of April 11, 2025.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State of incorporation) | (Commission File Number) | (IRS Employer No.) |
(Address of principal executive offices and Zip Code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| OTCQB |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
ITEM 5.02 – DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
On April 11th, 2025, James Cardwell resigned his position as CFO of the Corporation. At the same time the Board appointed Shrilakshmi Vadlapatla as CFO. Mr. Cardwell’s departure was not the result of any disagreements with management.
Ms. Vadlapatla, 40, is a seasoned boutique accountant with years of experience in audit compliance, SEC reporting, internal controls, Sarbanes-Oxley compliance and strategic financial management. With a strong background in GAAP and IFRS principles, earnings analysis, and external audits, she provides expertise in risk assessment, Sarbanes-Oxley compliance, and the development of robust financial policies and procedures. Ms. Vadlapatla holds a Bachelor of Commerce in Accounting from Osmania University, (India), 2005.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 14th, 2025
| Stemtech Corporation | ||
| By: | /s/ Charles Arnold | |
| Charles Arnold, CEO | ||
| 3 |